Elevate Capital Advisors LLC Purchases 2,409 Shares of AbbVie Inc. $ABBV

Elevate Capital Advisors LLC raised its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 33.4% during the third quarter, Holdings Channel reports. The fund owned 9,617 shares of the company’s stock after buying an additional 2,409 shares during the period. AbbVie comprises about 1.6% of Elevate Capital Advisors LLC’s investment portfolio, making the stock its 29th biggest position. Elevate Capital Advisors LLC’s holdings in AbbVie were worth $2,227,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Impact Capital Partners LLC lifted its stake in AbbVie by 7.9% in the third quarter. Impact Capital Partners LLC now owns 26,411 shares of the company’s stock worth $6,115,000 after purchasing an additional 1,940 shares during the last quarter. Octavia Wealth Advisors LLC increased its holdings in shares of AbbVie by 30.0% in the third quarter. Octavia Wealth Advisors LLC now owns 3,814 shares of the company’s stock worth $883,000 after buying an additional 881 shares during the period. Sutton Place Investors LLC bought a new stake in shares of AbbVie in the 3rd quarter valued at about $266,000. MBE Wealth Management LLC boosted its holdings in AbbVie by 4.3% during the 3rd quarter. MBE Wealth Management LLC now owns 5,419 shares of the company’s stock valued at $1,255,000 after acquiring an additional 225 shares during the period. Finally, Procyon Advisors LLC grew its position in AbbVie by 7.6% during the 3rd quarter. Procyon Advisors LLC now owns 27,325 shares of the company’s stock worth $6,327,000 after acquiring an additional 1,933 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie says it will build out its presence in the fast-growing obesity-treatment market, leveraging a weight‑loss drug it licensed from Danish biotech Gubra — opens a new growth avenue beyond core franchises. AbbVie plans to build out its presence in obesity market
• Positive Sentiment: AbbVie reached a three‑year drug‑pricing pact with the U.S. administration that includes a $100 billion U.S. R&D/investment pledge and exemptions from certain tariffs — reduces policy/tariff risk and signals regulatory cooperation. AbbVie inks latest White House drug pricing deal, scoring tariff reprieve as it makes $100B US investment pledge
• Positive Sentiment: AbbVie agreed to a ~$5.6B licensing partnership with RemeGen to access a PD‑1xVEGF bispecific oncology candidate — expands oncology pipeline and potential future revenue streams. AbbVie pens $5.6B pact with RemeGen to join PD-1xVEGF bispecific battle
• Positive Sentiment: AbbVie is acquiring a drug‑delivery system and an Arizona manufacturing facility from West Pharma and is spending on U.S. manufacturing capacity (including a reported $175M plant) — strengthens supply chain and supports on‑shore production. AbbVie to Acquire Drug Delivery System, Arizona Manufacturing Facility from West Pharma
• Neutral Sentiment: Management’s full transcript from the J.P. Morgan Healthcare Conference provides detail on strategy and pipeline positioning — useful for modeling but no single market‑moving surprise in the transcript itself. AbbVie Inc. (ABBV) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
• Neutral Sentiment: Several analyst/market pieces highlight bullish sentiment and long‑term value arguments for ABBV; these can support momentum but reflect secondary commentary rather than new company facts. Wall Street Bulls Look Optimistic About AbbVie (ABBV): Should You Buy?
• Neutral Sentiment: AbbVie joined industry calls for the FDA to update post‑approval change rules — a regulatory engagement that could benefit manufacturers broadly if successful but is a longer‑term policy push. AbbVie, Amgen, Lilly Lead Calls for FDA To Update Post-Approval Change Rules
• Negative Sentiment: The U.S. drug‑pricing agreement includes commitments to lower some U.S. prices and Medicaid impacts — this could weigh on near‑term revenue/margins for affected products even as tariff/other risks are reduced. ABBV Inks Drug Pricing Deal With Trump, Joins PD-1xVEGF Bandwagon

Analyst Upgrades and Downgrades

Several analysts have weighed in on ABBV shares. Cantor Fitzgerald set a $250.00 price objective on AbbVie and gave the company an “overweight” rating in a research report on Thursday, October 9th. JPMorgan Chase & Co. upped their price target on shares of AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a report on Monday, November 3rd. Wall Street Zen cut shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 3rd. Piper Sandler restated an “overweight” rating and issued a $289.00 price objective (up previously from $284.00) on shares of AbbVie in a research report on Wednesday, November 5th. Finally, Hsbc Global Res upgraded shares of AbbVie from a “hold” rating to a “strong-buy” rating in a report on Wednesday, December 10th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $246.89.

AbbVie Trading Up 0.7%

Shares of ABBV opened at $222.21 on Thursday. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81. The firm’s 50-day moving average price is $226.94 and its 200-day moving average price is $216.08. The firm has a market capitalization of $392.72 billion, a price-to-earnings ratio of 168.34, a PEG ratio of 0.92 and a beta of 0.36.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The company had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. During the same period in the prior year, the firm earned $3.00 earnings per share. AbbVie’s revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, research analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a dividend of $1.73 per share. This is a boost from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a dividend yield of 3.1%. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio is presently 496.97%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.